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Abstract
Introduction: To investigate the expression of EPLIN-α, epithelial protein lost in neoplasm, in
human breast cancer tissues/cells and investigate the cellular impact of EPLIN-α on breast cancer
cells.
Experimental design: EPLIN-α was determined in tumour (n = 120) and normal mammary
tissues (n = 32), and cancer cell lines (n = 16). Cell invasion, in vitro and in vivo growth of cells
transfected with EPLIN-α were evaluated using in vitro invasion assay, in vitro and in vivo tumour
model. Cellular migration was analysed using Electric Cell Impedance Sensing assays.
Results: Low level of EPLIN-α was seen in tumour tissues. Grade-2/3 tumours had significantly
lower levels of EPLIN-α compared with grade-1 (p = 0.047 and p = 0.046 vs grade-1, respectively).
Patients with poor prognosis had a significantly lower levels of EPLIN-α compared with those with
good prognosis (p = 0.0081). Patients who developed recurrence and died of breast cancer had
significantly lower levels of EPLIN-α compared with those who remained disease free (p = 0.0003
and p = 0.0008, respectively) (median follow-up 10 years). Patients with high levels of EPLIN-α
transcript had a longer survival than those with low levels. Over-expression of EPLIN-α in breast
cancer cells by way of transfection rendered cells less invasive, less motile and growing at a slower
pace in vitro and in vivo. An ERK inhibitor was shown to be able to abolish the effect of EPLIN
expression.
Conclusion: It is concluded that expression of EPLIN-α in breast cancer is down-regulated in
breast cancer cells and tissues, a change linked to the prognosis. EPLIN-α acts as a potential tumour
suppressor by inhibition of growth and migration of cancer cells.
Introduction
Epithelial protein lost in neoplasm, EPLIN, was first iden-
tified as a gene that is transcriptionally down-regulated in
oral cancer cells [1]. Two isoforms of EPLIN have been
identified known as EPLIN-α and EPLIN-β [2], which are
different by the appearance of an additional 160 amino
acids at the N-terminus of the beta isoform. EPLIN is
located along the actin stress fibres and focal adhesion
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plaques, indicating a possible role in cell morphology,
migration and adhesion. Indeed, it has been recently
shown to cross link and stabilise cytoskeletal filaments
and promote formation of stress fibres [3], by doing so
contributing to the inhibition of anchorage independent
growth in transformed cells, but not in non-transformed
cells [4].
EPLIN has been demonstrated to express at low levels in a
range of cancer cell lines. For example, 8 out of 8 of oral
cancer cell lines tested, 4 of 4 prostate cancer cells and 5 of
6 breast cancer cell lines were found to have low levels of
EPLIN transcript [3,5]. Although the investigation into the
biological function of EPLIN remains at preliminary stage,
the information of their role in cells and the cytoskeleton
and reduced expression in cancer cells indicate that the
molecule may act as a tumour suppressor. However, there
has been no clinical evidence to indicate as such. In a
molecular screening programme, we identified EPLIN-α
as one of the molecules whose expression was most aber-
rant.
The aim of the current study was to investigate the possi-
ble clinical implication of EPLIN-α in human breast can-
cer. Here, we first report that expression of EPLIN-α in
human breast cancer is aberrant and that the levels of
expression is linked to the clinical outcome of patients
with breast cancer and provide evidence that by affecting
cytoskeletal elements, EPLIN-α  reduced cell growth in
vitro and tumour growth in vivo. It is also a regulator of cel-
lular migration as demonstrated by an ECIS based analy-
sis.
Methods
Tissues and patients
Breast cancer cell line MDA MB-463, MDA MB-435s, MDA
MB-436, MCF10A. MCF-7, ZR 7–51, MDA MB-468, BT-
482, BT474, BT549, MDA MB-157, and MDA MB 231,
human fibroblast cell lines IBTG3 and MRC5 were pur-
chased from the European Collection of Animal Cell Cul-
tures (ECACC, Salisbury, England). These breast cancer
cell lines represented panel of cells with high invasiveness
(MDA MB-435s, MDA MB-231), low invasiveness (MCF-
7, ZR 7–51, MDA MB-463, MDA MB-436, MDA MB 468,
MDA MB-157, BT549) and immortalised mammary epi-
thelial cells (MCF-10A). Of the cell lines used, MCF-7,
MCF-10A, BT-474, ZR 7–51 are known ER positive,
remaining are ER negative (except BT482 and MDA MB-
463 of which ER status are not clear). Most breast cancer
cell lines are from ductal carcinoma which is the main
type of the tumour histological types in the present study,
except MDA MB-435s, MDA MB 436, MDA MB-468
which were initially described as from adenocarcinoma of
the breast. Human umbilical vein endothelial cells
(HUVEC) were purchased from TCS Biologicals (Oxford,
England). Human endothelial cell line (HECV) was
obtained from the Biology and Cellular and Molecular
Pathology Dept, Naples, Italy. Breast cancer tissues (n =
120) and normal background tissues (n = 32) were col-
lected immediately after surgery and stored in the deep
freezer until use. Patients were routinely followed clini-
cally after surgery. The median followup period was 120
months. The presence of tumour cells in the collected tis-
sues was verified by examination of frozen sections using
H & E staining by a consultant pathologist (ADJ). Clinical
details of the patients are given in table 1.
Materials and regents
Rabbit anti-EPLINα antibody was from CalbioChem
(Nottingham, England, UK). Cloning vector, pEF6/
TOPO/his was from Invitrogen, Pasley, Scotland, UK).
ROCK inhibitor was from Santa-Cruz Biotechnologies
Inc., PLC-γ inhibitor, JNK inhibitor, JAK inhibitor, ERK
inhibitor, MET inhibitor, Wortmannin, AG490 and
Wiskostatin were from CalBiochem, Nottingham, Eng-
land, UK.
Tissue processing and extraction of RNA and generation of 
cDNA
Over 20 frozen successive sections from the each tissue
sample were homogenised in a RNA extraction solution
using a hand held homogeniser to extract total RNA. The
concentration of RNA was quantified using a UV spectro-
photometer. 1 μg RNA was used to generate cDNA using
a commercially available RT kit (AbGene Laboratories,
Essex, England).
Table 1: Clinical and pathological information of the cohort
Groupings Sample numbers
Nodal status Node negative, n = 65 Node positive, n = 55
Grade Grade 1, n = 23 Grade 2, n = 41 Grade 3, n = 56
Histology Ductal, n = 94 Lobular, n = 14 Others, n = 12
TNM staging TNM1, n = 69 TNM2, n = 40 TNM3, n = 7 TNM4, n = 4
Clin.
outcome
Disease free,
n = 81
With Metastasis,
n = 7
With local recur.,
n = 5
Died of breast Cancer,
n = 20
Died of unrelated diseases,
n = 7Molecular Cancer 2008, 7:71 http://www.molecular-cancer.com/content/7/1/71
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Detection of EPLIN-α using RT-PCR
Routine RT-PCR was carried out using a PCR master mix
that was commercially available (AbGene). Primers were
designed using the Beacon Designer software (version 2,
Biosoft International, Palo Alto, California, USA), to
amplify regions of human EPLIN-α that have no signifi-
cant overlap with other known sequences and that the
amplified products span over at least one intron, based on
sequence accession number AF198455. The primers used
were: 5'AAGCAAAAATGAAAACGAAG'3 and 5'ACTGAAC
CTGACCGTACAGACACCCACCTTAGCAATAG'3. Reac-
tions were carried out at the following conditions: 94°C
for 5 minutes, 36 cycles of 94°C for 15 seconds, 55°C for
25 seconds and 72°C for 15 seconds. PCR products were
separated on a 2% agarose gel and photographed using a
digital camera mounted over a UV transluminator. β-actin
was used as a house keeping gene: 5'ATGA-
TATCGCCGCGCTCG'3 and 5'CGCTCGTGTAGGATCT-
TCA'3.
Quantitative analysis of EPLIN-α transcripts
The levels of EPLIN-α transcripts from the above-prepared
cDNA was determined using a real-time quantitative PCR,
based on the Amplifluor™ technology, modified from a
method previous reported [6]. Briefly, pairs of PCR prim-
ers were similarly designed using the Beacon Designer
software to that of conventional PCR primers, but to one
of the primer, an additional sequence was added, known
as the Z sequence (5'actgaacctgaccgtaca'3) which is com-
plementary to the universal Z probe (Intergen Inc.,
Oxford, England, UK). A Taqman detection kit for β-actin
was purchased from Perkin-Elmer. The reaction was car-
ried out using the following: Hot-start Q-master mix
(Abgene), 10 pmol of specific forward primer, 1 pmol
reverse primer which has the Z sequence, 10 pmol of
FAM-tagged probe (Intergen Inc.,), and cDNA from
approximate 50 ng RNA. The reaction was carried out on
IcyclerIQ™ (Bio-Rad, Hemel Hemstead, England, UK)
which is equipped with an optic unit that allows real time
detection of 96 reactions. The following condition was
used in the reaction: 94°C for 12 minutes, 50 cycles of
94°C for 15 seconds, 55°C for 40 seconds (the data cap-
ture step) and 72°C for 20 seconds. The levels of the tran-
scripts were generated from an internal standard that was
simultaneously amplified with the samples. Cytokeratin-
19 (CK19) was used to normalise cellularity during the
analysis and primers for CK19 were 5'CAGGTCCGAGGT
TACTGAC3' and 5'ACTGAACCTGACCGTACACACTT-
TCTGCCAGTGTGTCTTC'3, respectively [7]. Data are
shown here as either the number of transcripts, or as
EPLIN:CK19 ratio.
Immunohistochemical staining of EPLIN
Frozen sections of mammary tissues (32 paired normal
and 32 matched tumour tissues, as well as dissected
tumour tissues) were cut at a thickness of 6 μm using a cry-
ostat (Leica). The sections were mounted on super frost
plus microscope slides, air dried and then fixed in a mix-
ture of 50% acetone and 50% methanol for 15 minutes.
Staining for each molecule was conducted on all the slides
at the same time in a single batch to avoid variance in
experimental conditions. The sections were then placed in
"Optimax" wash buffer (a Tween 20 containing washing
buffer from Sigma, Poole, Dorset, England, UK) for 5 – 10
minutes to rehydrate. Sections were incubated for 20 mins
in a blocking solution that contained 10% horse serum
and probed with the primary antibody (rabbit anti-
human EPLIN, Calbiochem, used at dilution of 1:100, for
60 minutes). The dilution chosen here was based on the
evaluation test run, during which the antibody was tested
over a range of 1:10 to 1:1000. Primary antibodies were
omitted in the negative controls. Following extensive
washings, sections were incubated for 30 minutes in the
solution containing the secondary biotinylated antibody
(Multilink Swine anti-goat/mouse/rabbit immunoglobu-
lin). Following washings, Avidin Biotin Complex (Vector
Laboratories) was then applied to the sections followed
by extensive washings. Diaminobenzidine chromogen
(Vector Labs) was then added to the sections which were
incubated in the dark for 5 minutes. Sections were then
counter-stained in Gill's Haematoxylin and dehydrated in
ascending grades of methanol before clearing in xylene
and mounting under a cover slip.
Construction of expression vector for human EPLIN-α
Full length human EPLIN-α cDNA was generated from a
cDNA preparation of normal mammary tissues. The fol-
lowing primers which allowed amplification of the full
length human EPLIN-α  were used: 5'ATGGAAAATT-
GTCTAGGAGA'3(EPLINaExF1), 5'ATGGAAAATTGTCTA
GGAGAA'3 (EPLINaExF2) and 5'TCACTCTTCATCCT-
CATCCTC'3 (EPLINaExR1). The reaction was carried out
using high-fidelity master mix with proof reading
enzymes (AbGene). Correctly amplified product was T-A
cloned into a mammalian expression vector, pEF6/V5-his.
The ligated products were then used to transform the
TOP10 bacteria (Invitrogen) for amplification. Plasmid
was extracted from E. coli which had correct oriented
insert and purified. MDA MB 231 cells were transfected by
way of electroporation using an electroporator (Easyjet,
Flowgen). 48 hours after electroporation, selection
medium which contained blasticidin (5 μg/ml final con-
centration) was used to select stably transfected strains.
After verification of the expression, two stains that carried
high level EPLIN-α expression were established and sub-
sequently named as MDA-MB231EPLINexp3, and MDA-
MB231EPLINexp4. Wild type and cells transfected with con-
trol plasmid respectively named MDA-MB231wt, MDA-
MB231pEF/His, were used as controls during the studies.Molecular Cancer 2008, 7:71 http://www.molecular-cancer.com/content/7/1/71
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Electric cell-substrate impedance sensing (ECIS) based 
cellular motility and micromotion assays
The 9600 model of the ECIS instrument (Applied Bio-
physics Inc, NJ, US) were used for motility assay (wound-
ing assay) in the study and ECIS-1600R model for
wounding/cell modelling and micromotion analysis
[8,9]. Cell modelling was carried out using the ECIS RbA
modelling software, supplied by the manufacturer. The
8W10 arrays (8 well format with 10 probes in each well)
were used in the present study. ECIS measures the interac-
tion between cells and the substrate to which they are
attached via gold-film electrodes placed on the surface of
culture dishes. Following treating the array surface with a
Cysteine solution, the arrays were incubated with com-
plete medium for 1 hour. The same number of MDA-
MB231wt, MDA-MB231pEF/His, MDA-MB231EPLINexp3, or
MDA-MB231EPLINexp4 (250,000 per well) in the same vol-
ume of medium (400 μl) were added to each wells. After
3 hours when confluence was reached, the monolayer was
electrically wounded at 6 v for 30 seconds. Impedance and
resistance of the cell layer were immediately recorded for
a period of up to 20 hours. For micromotion analysis,
similarly prepared cells in the array were placed into the
1600R model. Micromotion was recorded at 4000 Hz for
15 minutes. Migration and micromotion were modelled
using the ECIS RbA cell modelling software.
In vitro invasion analysis and cell growth assay
This was performed as previously reported and modified
in our laboratory [10]. Briefly, transwell inserts (upper
chamber) with 8 μm pore size were coated with 50 μg/
insert of Matrigel and air-dried, before being rehydrated.
20,000 cells were added to each well, with or without
rhHGF/SF (recombinant human hepatocyte growth fac-
tor). After 72 hours, cells that had migrated through the
matrix and adhered to other side of the insert were fixed
and stained with 0.5% (w/v) crystal violet. Cells that had
invaded and stained with crystal violet were extracted with
10% (v/v) of acetic acid and absorbance obtained using a
multiplate reader.
For cell growth assay, MDA-MB-231WT, MDA-MB-231pEF6,
or MDA-MB-231EPLINexp cells were plated into 96 well
plate at 2,500 cells/well. Cells were fixed in 10% formal-
dehyde on the day of plating, and on days 1, 2, 3, 4, 5, and
6 after plating. The cells were then stained with 0.5% (w/
v) crystal violet. Following washing, stained crystal was
extracted with 10% (v/v) acetic acid and absorbance deter-
mined using a multiplate reader. The growth of cells are
shown here as absorbance (mean ± SD).
In vivo development of mammary tumour
Athymic nude mice (Nude CD-1) of 4–6 weeks old were
purchased from Charles River Laboratories, Kent, Eng-
land, UK and maintained in filter-toped units. Breast can-
cer cells in culture flasks were first washed using sterile
BSS and treated using EDTA-Trypsin buffer. After remov-
ing EDTA-Trypsin and washing, the single cell suspension
was prepared using serum free medium which also con-
tained 0.5 mg/ml Matrigel. The cell number in the suspen-
sion is 5 × 106/ml. 100 μl of this cell suspension
(containing 0.5 million cells) was injected subcutane-
ously at the left scapula area [10]. Three groups were
included: MDA MB231 wild type, MDA MB-231 control
transfection, and MDA-MB-231 transfected with EPLIN-α
expression constructs. Each tumour group included 6 ath-
ymic nude mice. Mice were weighed and tumour sizes
measured twice weekly for 4 weeks. Mice with weight loss
over 25% or tumour size larger than 1 cm in any dimen-
sion were terminated according to the UK Home Office
and UKCCCR guideline. The volume of the tumour was
determined using the formula: tumour volume = 0.523 ×
width2 × length. At the conclusion of the experiment, ani-
mals were terminally anaesthetised, primary tumours
were dissected, weighed and frozen at -80°C. Part of the
primary tumours was fixed for histological examination.
Statistical analysis was carried out using Mann-Whitney U
test and significant difference was taken at p < 0.05. Sur-
vival was analysed using Kaplan-Meier survival analysis
on SPSS 12.
Results
Expression of EPLIN-α in human breast tissues and breast 
cancer cell lines
We first analysed the expression pattern of EPLIN-α in
paired breast tissues and breast cancer cell lines. EPLIN-α
protein was found in the cytoplasmic region of normal
mammary epithelial cells. Stromal cells had very little
staining (figure 1a). This would indicate, to some degree,
that EPLIN-α is primarily located epithelial cells. How-
ever, in tumour tissues, EPLIN-α staining in cancer cells
was substantially weaker than in normal epithelial cells
(figure 1a). The pattern is largely supported by the analy-
sis of the EPLIN-α transcript using conventional PCR (fig-
ure 1b2). Tumour tissues did indeed show a weak signal
compared with normal tissues. Most breast cancer cell
lines showed a weak presence of EPLIN-α  transcript.
BT474 and MDA MB-468 showed a stronger signal of the
transcript (figure 1b1). Interestingly, two of the fibroblast
cell lines also showed a weak signal for EPLIN-α. Interest-
ingly, a human endothelial cells, HUVEC and HECV, had
little EPLIN-α transcript.
We went on to quantify the levels of EPLIN-α transcript in
breast tumour tissues. Although the levels of EPLIN-α in
breast cancer tissues was lower (27.4 ± 6.8 copies per 50
ng RNA) compared with normal tissues (38.8 ± 22), the
difference is not statistically significant (p = 0.06), prima-
rily due to the high level of variance seen in normal tissuesMolecular Cancer 2008, 7:71 http://www.molecular-cancer.com/content/7/1/71
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(Figure 1c). When EPLIN-α transcripts were normalised
by CK19, the EPLIN:CK19 ratio was 2888 ± 2412 in nor-
mal and 329 ± 167 in tumour tissues (p = 0.0495).
We further analysed the levels of EPLIN-α transcript in
connection with the grade of breast tumours. Figure 1e
has shown that grade 2 and grade 3 tumour had signifi-
cantly lower levels of EPLIN-α compared with grade 1
breast tumours (p = 0.047 and p = 0.046 vs grade 1,
respectively, insert – matched EPLIN:CK19 ratio). Further-
more, the relationship between EPLIN-α and TNM status
was also analysed. Figure 1d3 has clearly shown that there
appeared to be a stepwise decrease of levels of EPLIN-α
from TNM1 to TNM4 tumours. However, significant dif-
ference was only seen in TNM4 tumours when compared
with TNM1 tumours (p = 0.0029) (figure 1d). Although
node positive tumours had lower levels of EPLIN-α tran-
script (20.8 ± 6.8) when compared with node negative
tumours (32.8 ± 6.8), the difference was nonetheless
insignificant (figure 1f). We also compared the levels of
EPLIN-α in the main tumour types in the cohort. The lev-
els were seen similar between ductal and lobular tumours
(22.7 ± 6.8 vs 29.5 ± 20, p > 0.05).
Expression of EPLIN-α in breast tumour is correlated with 
prognosis
We have used the Nottingham Prognostic Index (NPI) as
an indicator to assess the relationship between EPLIN-α
EPLIN-α expression in breast cancer tissues and cell lines
Figure 1
EPLIN-α expression in breast cancer tissues and cell lines.a: Immunohistochemical staining of EPLIN-α in normal mam-
mary tissues (left panel) and tumour tissues (right panel) from different patients. The tumour tissues were from patients with 
different tumour grade. D was a grade-1 tumour (Patient ID 123), E a grade-2 tumour (ID 75a) and F grade-3 tumour (ID 113). 
Magnification was ×200 for the micrographs. b1: Detection of the EPLIN-α transcript using RT-PCR in a panel of human breast, 
endothelial and stromal fibroblast cell lines. b2: Detection of the EPLIN-α transcript in a panel of matched normal and tumour 
tissues. Actin was used as the housekeeping control. c: quantitative analysis of the EPLIN-α transcript in normal and tumour 
tissues. d: Levels of expression of EPLIN-α transcripts in breast tumour tissues in connection with TNM status (left; * p = 
0.0029 vs TNM1 tumours). e: Levels of expression of EPLIN-α in breast tumour tissues in connection with grade (left, * p < 
0.05 vs grade 1 tumours) and F: with nodal status (right). Inserts in d, e and f are values of EPLIN-α transcript that have been 
normalised by CK19 (shown as EPLIN:CK19 ratio).Molecular Cancer 2008, 7:71 http://www.molecular-cancer.com/content/7/1/71
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transcript and a predicted prognosis. Patients were
divided into three groups, good, moderate and poor prog-
nosis, based on the NPI values. It was found that patients
with poor prognostic index had the lowest levels of
EPLIN-α (figure 2 left) amongst three groups. The differ-
ence between patients with poor prognosis and good
prognosis was highly significant (p = 0.0081) (figure 2a).
a: EPLIN-α and its correlation with predicted prognosis (left) and clinical outcome (right)
Figure 2
a: EPLIN-α and its correlation with predicted prognosis (left) and clinical outcome (right). The predicted progno-
sis was based on the NPI value of each patient and that good, moderate and poor prognosis had NPI value either < 3.4, 3.4–5.4 
or > 5.4. * p = 0.0081 vs good prognostic group. b. Levels of EPLIN-α transcript and clinical outcome. * p = 0.0003, # p = 
0.0008 vs disease free patients. c and d: levels of EPLIN-α transcript and overall survival (c) and disease free survival (d). 
Patients with high levels of EPLIN-α transcript had a significantly longer overall (p = 0.0461, in c) and disease-free survival (p = 
0.0345, in d) than those with low levels of the transcript. Inserts in a and b are values of EPLIN-α transcript that have been nor-
malised by CK19 (shown as EPLIN:CK19 ratio).Molecular Cancer 2008, 7:71 http://www.molecular-cancer.com/content/7/1/71
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EPLIN-α expression is correlated with clinical outcome in 
patients with breast cancer
The current cohort has a 120 month follow up. Based on
the clinical outcome at the final followup, patients were
divided into those who remained disease free, with meta-
static diseases, with local recurrence, and those who died
of breast cancer (patients died of causes unrelated to
breast cancer was excluded from the current analysis). As
can be seen from figure 2b, patients who remained disease
had the highest levels of EPLIN-α amongst all the patients.
It is interesting to note that patients who developed local
recurrence and who died of breast cancer exhibited signif-
icantly lower levels compared with those who remained
disease free (p = 0.0003 and p = 0.0008, respectively).
A survival analysis using Kaplan-Meier method has shown
that patients with low EPLIN-α tumours had a shorter
overall survival (135.3 (123.6–147.1, 95%CI) months)
compared with those with high EPLIN-α tumours (141.7
(138.5–148.7) months, p = 0.0461) (figure 2c). Similarly,
low levels of EPLIN-α was associated with shorter disease
free survival (129.4 (116.3–142.2) months) compared
with high levels of EPLIN-α (140 (132.4–147.7) months),
p = 0.0345 (figure 2d).
Breast cancer cells over-expressing EPLIN-α were less 
invasive and had a slower pace of growth in vitro and in 
vivo
Using a matrigel based in vitro invasion assay, it was
shown that MDA MB231 cells which over-expressed
EPLIN-α by way of transfection had significantly reduced
invasiveness compared with both wild type and control
transfected cells (figure 3A). In vitro cell growth assay
showed a significant lower rate of growth of EPLIN-α
transfected breast cancer cells (Figure 3B).
In an athymic nude mice model, it was shown that EPLIN-
α  transfected breast cancer cells grew at a significantly
slower pace compared with control cells. The difference of
tumour size was seen from early time points (after 8 days),
and the overall difference between EPLIN-α transfected
and wild type or transfection control both were highly sig-
nificant (p < 0.001 by two-way ANOWA) (figure 3C).
EPLIN-α expression and impact on in vitro invasion(A), in vitro growth (B) and in vivo tumour growth (C) of  breast cancer cells Figure 3
EPLIN-α expression and impact on in vitro invasion(A), in vitro growth (B) and in vivo tumour growth (C) of 
breast cancer cells. * p < 0.05 vs respective controls; # p < 0.001 vs control wild type and control groups.Molecular Cancer 2008, 7:71 http://www.molecular-cancer.com/content/7/1/71
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Electric cell impedance sensing (ECIS) based cell motility 
assay
Here, we adopted the Electric Cell Impedance Sensing
(ECIS) method to investigate the impact of EPLIN-α over-
expression on cell motility. As shown in Figure 4A, EPLIN-
α over-expressing breast cancer cells showed a dramatic
slowdown in recovery after electric wounding. Using
ECIS-RbA modelling system, it was shown that EPLIN-α
over-expression in the MDAMB231EPLINexp cells resulted in
a significant reduction in both resistance and capacitance,
when compared with both the wild type cells and the con-
trol cells (figure 4B and 4C).
In searching for the potential pathway(s) that may be
responsible for the action of EPLIN-α , we have screened
a panel of small molecule inhibitors to some of the key
EPLIN-α expression on cell migration as analysed by ECIS
Figure 4
EPLIN-α expression on cell migration as analysed by ECIS. A: wounding assays. Cells were first wounded at 6 v for 30 
sec. The impedance change was shown. Electrode – A1: MDA-MB231wt, A2: MDA-MB231pEF/His, A3: MDA-MB231EPLINexp3, A4: 
MDA-MB231EPLINexp4. The breast cancer cells which over-expressed EPLIN-α showed a markedly reduced migration. B and C: 
ECIS RbA modelling of cell motility indicated a significant reduction of motility in EPLIN-α transfected cells as shown by resist-
ance in B and capacitance in C. * p < 0.01 vs MDA-MB231wt and MDA-MB231pEF/His.Molecular Cancer 2008, 7:71 http://www.molecular-cancer.com/content/7/1/71
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signalling pathways that are linked to cell motility. They
included ROCK inhibitor, JAK3 inhibitor, JNK inhibitor,
PI3K inhibitor, PKC inhibitor and ERK inhibitor. Only the
ERK inhibitor was seen to partially restore the inhibitory
effect of EPLIN-α on the motility of the cancer cells as
shown in figure 5. ERK inhibitor has only a marginal
effect on the motility of the control breast cancer cells,
however, it reverse the inhibition of motility in the MDA
MB231EPLINexp cells to nearing the control level. This was
more obvious at the early phase (within 2 hours after
wounding) (figure 5).
Discussion
In the current study, we have shown that EPLIN-α , an epi-
thelial protein frequently lost in cancer cells, is also aber-
rantly expressed in clinical breast tumour tissues. We also
report that the levels of EPLIN-α are correlated with the
clinical outcomes and long term survival of the patients
with breast cancer. The study further demonstrates that
expression of EPLIN-α linked to the reduction of growth
of breast cancer cells in vitro and in vivo, and inhibition of
cellular migration via an ERK dependent pathway.
EPLIN has been found to be transcriptionally expressed at
lower levels in a limited number of tumour cells, includ-
ing breast cancer cells [1-3]. This is clearly seen in the
present study in which only few of the breast cancer cell
lines expressed the gene transcript. Perhaps the most
important observation seen in the present study is the link
between the level of EPLIN expression and the clinical
outcome. An inverse correlation was seen between the
level of the EPLIN transcripts and tumour grade, nodal
status and tumour staging. A highly significant link was
seen between low levels of expression and a poor clinical
outcome and shorter disease free and overall survival.
These data clearly indicate that EPLIN may act as a poten-
tial prognostic indicator and that the molecule may act as
a protective factor in patients with breast cancer. Informa-
tion of the clinical relevant of EPLIN in human cancers in
the literature of any type is limited. In another recent
ERK inhibitor reversed the action of EPLIN-α , an ECIS based wounding analysis
Figure 5
ERK inhibitor reversed the action of EPLIN-α , an ECIS based wounding analysis. Wild type, control cells and 
EPLIN-α expression MDA MB231 cells were tested in the absence or presence of ERK inhibitor. The reduction of migration in 
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study, there has been indication that EPLIN transcript may
also lost in colorectal cancer tissues [11]. The present
study is the first to demonstrate a clear clinical relevance
between EPLIN-α and clinical outcome.
This important clinical link has potential cellular explana-
tions, as demonstrated in the present study and indeed in
the literature. EPLIN-α protein was shown to be an actin
cross linking protein that bundles actin in the cells and
stabilises the cytoskeletal filaments. By doing so, EPLIN
protein inhibits cell motility [5,12]. In the present study,
we have also shown that forced expression of EPLIN-α in
the breast cancer cell line, MDA MB-231 which is negative
in EPLIN-α  expression, resulted in the cells to be less
aggressive, namely with reduced migration, invasion and
in vitro growth. The EPLIN-α  expressing cells also dis-
played a significantly reduced rate of growth in vivo. Col-
lectively, the present study shows that EPLIN, a potential
cell migration regulating protein, is inversely associated
with the aggressiveness and clinical outcome of human
breast cancers. This is likely via its inhibitory role on cell
growth and migration.
Although EPLIN has been shown to be an actin bundling
protein, the precise mechanism is yet to be fully estab-
lished. It has been shown that EPLIN inhibits the ARP2
mediated nucleation of actin filaments. During the prepa-
ration of the manuscript, two reports have shown that
EPLIN also mediates the linkage between the Cadherin/
catenin complex and F actin [13] and that one potential
pathway in these links is the extracellular signal-regulated
kinase (ERK) pathway [14]. These recent findings support
the present study which demonstrates that inhibition of
ERK pathway resulted in reversal of EPLIN mediated
reduction of cellular migration. This is interesting, as ERK
has becoming a therapeutic target in recent years.
In conclusion, EPLIN-α is a powerful regulator of the cel-
lular motility of breast cancer cells. Breast cancer cells
expressing EPLIN-α are less motile and grow slowly in
vivo. Together with the clinical relevance as demonstrated
in the present study, EPLIN-α is an important prognostic
indicator and may be an important target when consider-
ing therapies. We are currently examining the molecular
pathways involved in EPLIN-α mediated cell migration.
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